The Limited Times

Now you can see non-English news...

The caregiver arrives for patients with vision problems

2020-07-07T05:26:36.554Z


Accompanying the patient to the hospital for therapies, managing clinical appointments and transportation: the new "caregiver on demand" service dedicated to people being treated for retinal diseases is designed to assist at 360 degrees in the therapeutic process. The initiative, launched by the pharmaceutical company Novartis in collaboration with the startup UGO, has just started in a pilot phas...


Accompanying the patient to the hospital for therapies, managing clinical appointments and transportation: the new "caregiver on demand" service dedicated to people being treated for retinal diseases is designed to assist at 360 degrees in the therapeutic process. The initiative, launched by the pharmaceutical company Novartis in collaboration with the startup UGO, has just started in a pilot phase in the cities of Milan, Monza, Genoa, Foggia and in their respective neighborhoods.
Different degenerative eye diseases, which can lead to blindness, such as glaucoma, retinopathies and age-related macular degeneration, require continuous therapies over time. The service offered by UGO ensures these visually impaired patients the opportunity to regularly face the course of care in the hospital. The operators will in fact provide logistical, physical and psychological support, helping not to skip hospital therapy and follow-up appointments, orienting oneself in the structure and managing the ward's hours and rules, which is especially important in light of the changes made for the Covid-19 emergency.
The specialist to identify the patients to whom to allocate the support, on the basis of criteria such as physical fragility, for example a very poor vision or reduced mobility, but also social isolation and the lack of help from family members. All UGO caregivers are trained to guarantee quality and safety, in compliance with the prevention standards and directives of hospitals, and their work is constantly digitally tracked and monitored through feedback from other users.
"This project allows us to offer concrete help to patients with retinal diseases, ensuring them qualified assistance in the management of therapy", underlines Luca Vergari, Head of Franchise Ophtha of Novartis Italia. "In degenerative ophthalmic diseases - he continues - the timeliness of treatments and regular adherence to therapy are determining factors for the success of the treatment. For Novartis, being close to these patients therefore means not only making innovative drugs available to them but also identifying solutions to ensure the effectiveness of the therapeutic path and at the same time relieve the health structures from further organizational burdens ". The service is in fact free for users and without costs for public health.

In collaboration with:
Novartis

Source: ansa

All life articles on 2020-07-07

You may like

News/Politics 2024-03-07T06:17:19.672Z

Trends 24h

Life/Entertain 2024-03-28T17:17:20.523Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.